{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:29:35Z","timestamp":1789529375162,"version":"build-2803163510"},"reference-count":56,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ExxonMobil"},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["101103076"],"award-info":[{"award-number":["101103076"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,6,13]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Artemisinin-based combination therapies (ACTs) remain the WHO-recommended treatment for uncomplicated\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      malaria. However, the emergence and spread of artemisinin resistance (ART-R) threatens ACT efficacy. ART-R is phenotypically expressed as delayed parasite clearance, which can facilitate ACT partner drug resistance. ART-R has been causally linked to specific mutations in the\n                      <jats:italic>Pfkelch13<\/jats:italic>\n                      gene.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      The systematic review and associated meta-analysis aim to determine the correlation between\n                      <jats:italic>Pfkelch13<\/jats:italic>\n                      (alleles present in the\n                      <jats:italic>Kelch13<\/jats:italic>\n                      gene region of the\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      parasite) genotypes and clinical and parasitological response to ACTs from a globally representative data set pooling individual patient data (IPD) from eligible published and unpublished studies. The eligibility criteria include\n                      <jats:italic>Pfkelch13<\/jats:italic>\n                      genotyping results at baseline complemented by individually linked parasitological and clinical assessments following artemisinin-based treatment. The data will be curated, standardised and analysed using this proposed statistical analysis plan (SAP), adhering to PRISMA-IPD (PRISMA, Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. Our SAP will apply hierarchical modelling to assess the effect of the\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      parasite\n                      <jats:italic>Pfkelch13<\/jats:italic>\n                      mutations on parasite clearance half-life and therapeutic efficacy across different regions. This will include study sites as random effects in the model and potential predictors such as age, sex, baseline parasite load and other potential effect modifiers as fixed effects. This analysis will enhance the understanding of the influence of\n                      <jats:italic>Pfkelch13<\/jats:italic>\n                      mutations on malaria treatment outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Data were obtained with informed consent and ethical approvals from the relevant countries and were pseudonymised before curation in the Infectious Diseases Data Observatory (IDDO)\/WorldWide Antimalarial Resistance Network (WWARN) repository. Data ownership remains with contributors. This IPD meta-analysis met the Oxford Tropical Research Ethics Committee criteria for waiving ethical review, as it is a secondary analysis of existing pseudonymised data. The resulting peer-reviewed publication and conference proceedings will help strengthen and enhance the efficiency of ART-R surveillance and response and support policy decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42019133366.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-100251","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T16:32:13Z","timestamp":1752510733000},"page":"e100251","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Investigating the relationship between\n                    <i>Pfkelch13<\/i>\n                    mutations and response to artemisinin-based treatment for uncomplicated falciparum malaria: a protocol for a systematic review and individual patient data meta-analysis"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2655-8518","authenticated-orcid":false,"given":"Stephanie","family":"van Wyk","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Cape Town, Rondebosch, South Africa"},{"name":"IDDO, World Wide Antimalarial Resistance Network (WWARN), Oxford, UK"},{"name":"Mitigating Antimalarial Resistance Consortium in South-East Africa, Cape Town, South Africa"},{"name":"Infectious Diseases Data Observatory, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabin","family":"Dahal","sequence":"additional","affiliation":[{"name":"Infectious Diseases Data Observatory, Oxford, UK"},{"name":"World Wide Antimalarial Resistance Network (WWARN), Oxford, UK"},{"name":"Department of Nuffield, University of Oxford Centre for Tropical Medicine and Global Health, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chistevy","family":"Vouvoungui","sequence":"additional","affiliation":[{"name":"IDDO, World Wide Antimalarial Resistance Network (WWARN), Oxford, UK"},{"name":"Infectious Diseases Data Observatory, Oxford, UK"},{"name":"Department of Nuffield, University of Oxford Centre for Tropical Medicine and Global Health, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhol S","family":"Ayuen","sequence":"additional","affiliation":[{"name":"IDDO, World Wide Antimalarial Resistance Network (WWARN), Oxford, UK"},{"name":"Infectious Diseases Data Observatory, Oxford, UK"},{"name":"University of Oxford Centre for Tropical Medicine and Global Health, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Shokraneh","sequence":"additional","affiliation":[{"name":"IDDO, World Wide Antimalarial Resistance Network (WWARN), Oxford, UK"},{"name":"Infectious Diseases Data Observatory, Oxford, UK"},{"name":"University of Oxford Centre for Tropical Medicine and Global Health, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aboubakar","family":"Soma","sequence":"additional","affiliation":[{"name":"IDDO, World Wide Antimalarial Resistance Network (WWARN), Oxford, UK"},{"name":"Infectious Diseases Data Observatory, Oxford, UK"},{"name":"Fondation Congolaise pour la recherche M\u00e9dicale, Brazzaville, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Watson","sequence":"additional","affiliation":[{"name":"IDDO, World Wide Antimalarial Resistance Network (WWARN), Oxford, UK"},{"name":"Infectious Diseases Data Observatory, Oxford, UK"},{"name":"University of Oxford Centre for Tropical Medicine and Global Health, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Guerin","sequence":"additional","affiliation":[{"name":"Infectious Diseases Data Observatory, Oxford, UK"},{"name":"World Wide Antimalarial Resistance Network (WWARN), Oxford, UK"},{"name":"University of Oxford Centre for Tropical Medicine and Global Health, Oxford, UK"},{"name":"University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen I","family":"Barnes","sequence":"additional","affiliation":[{"name":"Mitigating Antimalarial Resistance Consortium in South-East Africa, Cape Town, South Africa"},{"name":"Infectious Diseases Data Observatory, Oxford, UK"},{"name":"World Wide Antimalarial Resistance Network (WWARN), Oxford, UK"},{"name":"Department of Clinical Pharmacology, University of Cape Town, Rondebosch, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"2025121219382866000_15.7.e100251.1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa172"},{"key":"2025121219382866000_15.7.e100251.2","unstructured":"WHO . World Malaria Report, Available: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024"},{"key":"2025121219382866000_15.7.e100251.3","unstructured":"World Health Organization . Strategy to respond to antimalarial drug resistance in Africa. Global Malaria Programme, Available: https:\/\/www.who.int\/publications\/i\/item\/9789240060265"},{"key":"2025121219382866000_15.7.e100251.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00141-5"},{"key":"2025121219382866000_15.7.e100251.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-024-01008-2"},{"key":"2025121219382866000_15.7.e100251.6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014","journal-title":"Nature New Biol"},{"key":"2025121219382866000_15.7.e100251.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314981"},{"key":"2025121219382866000_15.7.e100251.8","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1207-3"},{"key":"2025121219382866000_15.7.e100251.9","unstructured":"WHO . Malaria: Artemisinin partial resistance, Available: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/artemisinin-resistance"},{"key":"2025121219382866000_15.7.e100251.10","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-018-1207-3","article-title":"Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments-a WWARN individual patient data meta-analysis","volume":"17","author":"Amaratunga","year":"2019","journal-title":"BMC Med"},{"key":"2025121219382866000_15.7.e100251.11","doi-asserted-by":"crossref","DOI":"10.1007\/s00436-024-08203-3","article-title":"The prevalence of Pfk13 polymorphism in malaria patients treated with artemisinin-based therapy: a systematic review and meta-analysis","volume":"123","author":"Hung","year":"2024","journal-title":"Parasitol Res"},{"key":"2025121219382866000_15.7.e100251.12","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJPDDR.2021.06.001"},{"key":"2025121219382866000_15.7.e100251.13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/AAC.01818-18","article-title":"Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda","volume":"63","author":"Asua","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025121219382866000_15.7.e100251.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1005-2"},{"key":"2025121219382866000_15.7.e100251.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00142-0"},{"key":"2025121219382866000_15.7.e100251.16","doi-asserted-by":"publisher","DOI":"10.1111\/MEC.15706"},{"key":"2025121219382866000_15.7.e100251.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101746"},{"key":"2025121219382866000_15.7.e100251.18","doi-asserted-by":"publisher","DOI":"10.3201\/eid2701.203527"},{"key":"2025121219382866000_15.7.e100251.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211803)"},{"key":"2025121219382866000_15.7.e100251.20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab352"},{"key":"2025121219382866000_15.7.e100251.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-021-03987-6","article-title":"Prevalence of potential mediators of artemisinin resistance in African isolates of Plasmodium falciparum","volume":"20","author":"Owoloye","year":"2021","journal-title":"Malar J"},{"key":"2025121219382866000_15.7.e100251.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210956"},{"key":"2025121219382866000_15.7.e100251.23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3347\/PHD.22140","article-title":"Monitoring antimalarial drug-resistance markers in Somalia","volume":"61","author":"Jalei","year":"2023","journal-title":"Parasites Hosts Dis"},{"key":"2025121219382866000_15.7.e100251.24","doi-asserted-by":"crossref","unstructured":"Fola AA , Feleke SM , Mohammed H , et al . Clonal spread of Plasmodium falciparum candidate artemisinin partial resistance Kelch13 622I mutation and co-occurrence with pfhrp2\/3 deletions in Ethiopia. MedRxiv 2023;2023. doi:10.1101\/2023.03.02.23286711","DOI":"10.1101\/2023.03.02.23286711"},{"key":"2025121219382866000_15.7.e100251.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02641-9"},{"key":"2025121219382866000_15.7.e100251.26","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4269\/ajtmh.23-0382","article-title":"Screening for K13-Propeller Mutations Associated with Artemisinin Resistance in Plasmodium falciparum in Yambio County (Western Equatoria State, South Sudan)","volume":"109","author":"Molina-de la Fuente","year":"2023","journal-title":"Am J Trop Med Hyg"},{"key":"2025121219382866000_15.7.e100251.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-020-03165-0","article-title":"Assessment of Plasmodium falciparum drug resistance molecular markers from the Blue Nile State, Southeast Sudan","volume":"19","author":"Mohamed","year":"2020","journal-title":"Malar J"},{"key":"2025121219382866000_15.7.e100251.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.11.026"},{"key":"2025121219382866000_15.7.e100251.29","doi-asserted-by":"crossref","unstructured":"Juliano JJ , Giesbrecht DJ , Simkin A , et al . Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania. medRxiv 2023.:2023.11.07.23298207. doi:10.1101\/2023.11.07.23298207","DOI":"10.1101\/2023.11.07.23298207"},{"key":"2025121219382866000_15.7.e100251.30","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-024-04896-0","article-title":"Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021","volume":"23","author":"Bakari","year":"2024","journal-title":"Malar J"},{"key":"2025121219382866000_15.7.e100251.31","doi-asserted-by":"crossref","unstructured":"Ishengoma DS , Mandara CI , Bakari C . Evidence of artemisinin partial resistance in north-western tanzania: clinical and drug resistance markers study. Infectious Diseases (except HIV\/AIDS) [Preprint]. doi:10.1101\/2024.01.31.24301954","DOI":"10.1101\/2024.01.31.24301954"},{"key":"2025121219382866000_15.7.e100251.32","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01299-23","article-title":"Escalating Plasmodium falciparum K13 marker prevalence indicative of artemisinin resistance in southern Rwanda","volume":"68","author":"van Loon","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025121219382866000_15.7.e100251.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02551-w"},{"key":"2025121219382866000_15.7.e100251.34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3656"},{"key":"2025121219382866000_15.7.e100251.35","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.19-0706"},{"key":"2025121219382866000_15.7.e100251.36","unstructured":"WorldWide Antimalarial Resistance Network . Terms of Submission, Available: https:\/\/www.wwarn.org\/tools-resources\/terms-submission"},{"key":"2025121219382866000_15.7.e100251.37","unstructured":"WorldWide Antimalarial Resistance Network . Infectious Diseases Data Observatory (2023) IDDO SDTM Implementation Manual. 2022. Available: https:\/\/wiki.iddo.org\/en\/Data-Engineering\/IDDO-SDTM-Implementation-Manual"},{"key":"2025121219382866000_15.7.e100251.38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001823","article-title":"Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach","volume":"12","author":"White","year":"2015","journal-title":"PLoS Med"},{"key":"2025121219382866000_15.7.e100251.39","unstructured":"Levis B , Takwoingi Y , Collins GS , et al . Evaluating risk of bias and applicability in individual participant data meta-analyses. 2020. Available: https:\/\/abstracts.cochrane.org\/2020-abstracts\/evaluating-risk-bias-and-applicability-individual-participant-data-meta-analyses"},{"key":"2025121219382866000_15.7.e100251.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2025121219382866000_15.7.e100251.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"2025121219382866000_15.7.e100251.42","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c221","article-title":"Meta-analysis of individual participant data: rationale, conduct, and reporting","volume":"340","author":"Riley","year":"2010","journal-title":"BMJ"},{"key":"2025121219382866000_15.7.e100251.43","unstructured":"World Health Organization . The World Malaria Report, 2024 in Addressing inequity in the global malaria response, Geneva. 2024."},{"key":"2025121219382866000_15.7.e100251.44","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.21-0214"},{"key":"2025121219382866000_15.7.e100251.45","unstructured":"Uganda National Malaria Control Programme Programme . Efficacy and safety of artemether-lumefantrine, pyronaridine-artesunate, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in children in Uganda. 2024."},{"key":"2025121219382866000_15.7.e100251.46","unstructured":"World Health Organization . WHO Malaria Threats Map, Available: https:\/\/apps.who.int\/malaria\/maps\/threats"},{"key":"2025121219382866000_15.7.e100251.47","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00207-22","article-title":"Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria among Children in Western Kenya, 2016 to 2017","volume":"66","author":"Westercamp","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025121219382866000_15.7.e100251.48","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0750-4"},{"key":"2025121219382866000_15.7.e100251.49","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33873-x","article-title":"Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda","volume":"13","author":"Tumwebaze","year":"2022","journal-title":"Nat Commun"},{"key":"2025121219382866000_15.7.e100251.50","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1473-3099(24)00413-4","article-title":"Resistant malaria parasites gaining momentum in Africa","volume":"24","author":"Mlugu","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025121219382866000_15.7.e100251.51","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00487-9"},{"key":"2025121219382866000_15.7.e100251.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60484-X"},{"key":"2025121219382866000_15.7.e100251.53","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-018-2182-z","article-title":"Poor response to artesunate treatment in two patients with severe malaria on the Thai-Myanmar border","volume":"17","author":"Phyo","year":"2018","journal-title":"Malar J"},{"key":"2025121219382866000_15.7.e100251.54","doi-asserted-by":"publisher","DOI":"10.3201\/eid2304.161872"},{"key":"2025121219382866000_15.7.e100251.55","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30391-3"},{"key":"2025121219382866000_15.7.e100251.56","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.22-0148"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-100251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:38:42Z","timestamp":1765597122000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-100251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":56,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,8]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2025-100251"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-100251","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}